Belite Bio, Inc. ADR (BLTE) AI Stock Analysis

75 Followers

Belite Bio, Inc. ADR

(NASDAQ:BLTE)

Select Model

Rating:68Neutral

Price Target:$185.00▲(12.56% Upside)

Action:reiterated

Date:11/13/26

Overall score reflects a strong balance sheet and a positive regulatory/launch-readiness narrative from the earnings call, supported by constructive technical momentum. These are tempered by the core financial reality of no revenue with widening losses and cash burn, and limited valuation support given the negative P/E and no dividend yield.

Positive Factors

Low leverage and strong capital baseExtremely low debt and a large equity base give Belite substantial financial flexibility to fund clinical development and commercialization preparation. This reduces near-term balance-sheet pressure and supports continued investment while the company works toward potential product approval.

Negative Factors

No commercial revenueBelite currently has no product revenue to offset research, development, and commercial preparation costs. Its fundamental outlook therefore remains dependent on successful regulatory approval and eventual market uptake, leaving the business without an operating revenue base over the next several months.

Belite Bio, Inc. ADR (BLTE) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $6.62B
Dividend Yield: ―
Average Volume (3M): 180.42K
Price to Earnings (P/E): -57.5
Beta (1Y): 0.80
Revenue Growth: ―
EPS Growth: -47.46%
Country: US
Employees: 41
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Belite Bio, Inc. ADR Business Overview & Revenue Model

Company Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disea...

How the Company Makes Money

Belite Bio is a pre-commercial, clinical-stage biotechnology company. Public, product-based revenue streams from approved products are not available (null). The company historically funds operations primarily through financing activities typical for...

Belite Bio, Inc. ADR Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:5.40%|Next Earnings Date:May 10, 2023

Earnings Call SentimentPositive

The call was predominantly positive, reflecting substantial regulatory progress toward a potential Tinlarebant launch, a strong cash position, supportive payer feedback, expanding international submissions, and continued commercial preparation. These positives were tempered by higher operating expenses and net losses, as well as unresolved details around the product label and the design and timing of the geographic atrophy interim analysis.

Positive Updates

FDA Priority Review and February 2027 PDUFA Date

The FDA accepted the NDA for Tinlarebant in Stargardt disease for priority review, with a PDUFA date of February 12, 2027. The FDA also informed the company that it will not convene an advisory committee meeting for the NDA.

Negative Updates

Higher R&D Expenses

Third-quarter GAAP R&D expenses increased to $15.5 million from $10.3 million in the third quarter of 2025. The increase was primarily attributed to higher active pharmaceutical ingredient manufacturing and drug-product manufacturing expenses, consulting fees, and sponsorship funding. Non-GAAP R&D expenses increased to $14.7 million from $8.0 million.

Company Guidance

Belite Bio said its current cash runway is sufficient to support the potential commercialization of Tinlarebant, subject to regulatory approval, and to continue advancing its pipeline; the FDA PDUFA date is February 12, 2027, the company plans to conduct the GA interim analysis after the February PDUFA date is completed, and it will definitely start the PIP study at Moorfields Eye Hospital in this quarter, so before the end of the year. The company is planning for other regulatory submissions to roll-out, expects to market the drug in Japan itself, and said rare disease pricing is still the guidance it can provide, with pricing expected to reflect the rare disease profile, clinical benefit and the unmet need and benchmarking with other rare ophthalmology and pediatric orphan therapies.

Belite Bio, Inc. ADR Financial Statement Overview

Summary

Financial profile is mixed for a development-stage biotech: income statement and cash flow are weak (no revenue, widening losses, and increasing operating/FCF burn), but the balance sheet is a major strength with very low debt and substantial equity/cash resources that can fund R&D and runway.

Income Statement

18Very Negative

Balance Sheet

86Very Positive

Cash Flow

32Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	-198.00K	-30.00K
EBITDA	-114.22M	-77.15M	-35.67M	-31.20M	-12.43M	-9.64M
Net Income	-102.36M	-77.61M	-36.14M	-31.63M	-12.65M	-9.67M
Balance Sheet
Total Assets	791.58M	780.56M	152.13M	94.64M	44.27M	18.35M
Cash, Cash Equivalents and Short-Term Investments	0	492.42M	145.15M	88.16M	42.09M	17.34M
Total Debt	0	429.00K	537.00K	886.00K	866.00K	31.81M
Total Liabilities	14.95M	10.07M	6.31M	4.21M	2.77M	33.44M
Stockholders Equity	776.64M	770.49M	145.82M	90.43M	41.50M	-15.09M
Cash Flow
Free Cash Flow	-10.56K	-37.17M	-29.39M	-29.90M	-11.85M	-7.55M
Operating Cash Flow	-10.38K	-36.99M	-29.23M	-29.84M	-11.46M	-7.47M
Investing Cash Flow	-303.73K	-305.11M	-110.57M	-63.00K	-394.00K	-56.00K
Financing Cash Flow	510.12K	663.23M	83.59M	75.96M	36.96M	-583.00K

Belite Bio, Inc. ADR Technical Analysis

Technical Analysis SentimentPositive

Last Price164.35

Price Trends

50DMA160.88Positive

100DMA159.11Positive

200DMA160.11Positive

Market Momentum

MACD1.22Negative

RSI57.29Neutral

STOCH82.90Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLTE, the sentiment is Positive. The current price of 164.35 is above the 20-day moving average (MA) of 152.85, above the 50-day MA of 160.88, and above the 200-day MA of 160.11, indicating a bullish trend. The MACD of 1.22 indicates Negative momentum. The RSI at 57.29 is Neutral, neither overbought nor oversold. The STOCH value of 82.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLTE.

Belite Bio, Inc. ADR Risk Analysis

Belite Bio, Inc. ADR disclosed 111 risk factors in its most recent earnings report. Belite Bio, Inc. ADR reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.We no longer qualify as an "emerging growth company" and, as a result, we are no longer able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies.Q4, 2025

2.We will rely on third parties to manufacture clinical and commercial supplies of tinlarebant and other product candidates and future products.Q4, 2025

Belite Bio, Inc. ADR Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BLTE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLTE	68Neutral	$6.90B	-57.47	-16.96%	―	―	-47.46%
RYTM	64Neutral	$7.62B	-39.66	-83.68%	―	61.04%	6.14%
MIRM	57Neutral	$6.09B	-6.17	-734.00%	―	42.18%	-1679.32%
PTCT	56Neutral	$5.29B	-48.47	57.10%	―	-35.05%	-113.73%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TVTX	48Neutral	$4.95B	-32.47	-186.46%	―	49.38%	-58.47%
XENE	46Neutral	$4.03B	-8.61	-39.80%	―	-100.00%	-21.09%

* Healthcare Sector Average

Performance Comparison

BLTE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BLTE	Belite Bio, Inc. ADR	164.35	47.44	40.58%
PTCT	PTC Therapeutics	63.49	-12.11	-16.02%
TVTX	Travere Therapeutics, Inc.	50.65	15.21	42.92%
XENE	Xenon Pharmaceuticals	40.48	-0.13	-0.32%
RYTM	Rhythm Pharmaceuticals	115.02	14.33	14.23%
MIRM	Mirum Pharmaceuticals	93.99	21.78	30.16%

Belite Bio, Inc. ADR Corporate Events

Belite Bio Reports Third-Quarter Results and Tinlarebant Regulatory Progress

Nov 12, 2026

Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases, including tinlarebant for Stargardt disease type 1 (STGD1) and clinical programs in geographic atrophy (GA). On November 12, 2026...

Belite Bio Uplists to Nasdaq Global Select Market as Retinal Drug Program Advances

Oct 19, 2026

Belite Bio, Inc. announced on October 19, 2026 that it has received Nasdaq approval to transfer its securities listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher-tier market commencing the same day u...

Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease

Sep 8, 2026

On September 8, 2026, Belite Bio announced it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for tinlarebant to treat Stargardt disease type 1, a rare inherited retinal disorder that currently has no approved t...

Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out

Aug 13, 2026

On August 12, 2026, Belite Bio reported unaudited second-quarter 2026 results and a corporate update, highlighted by the U.S. Food and Drug Administration’s acceptance of its New Drug Application for tinlarebant in Stargardt disease type 1 with Prior...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Belite Bio, Inc. ADR AI Stock Analysis